Total Funding
12
35
Total FundingVenture - Series Unknown raised
Growth Score
-7 pts
Heat Score
-27 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
160482
Dyve creates novel therapeutics using proprietary science that leverages the skin as a portal for systemic delivery.
- Chuck Harbert: CSO
- Ryan Beal: Co-founder and CEO
About the Company
Dyve creates novel therapeutics using proprietary science that leverages the skin as a portal for systemic delivery. The company is rapidly developing a strong pipeline across a broad range of therapeutic areas based around its proprietary science. Dyve’s most advanced asset, DYV-700, is in phase 2 for the treatment of acute gout using a mechanism
of action enabled by Dyve’s science. The company has PK data demonstrating injection-like delivery across a broad range of molecules.
It was founded in 2014 and is headquartered in Thousand Oaks, California.
